StereotaxisSTXS +0.31%66 Beneish M-Score is -2.06 as of Jun. 25, 2026. GuruFocus rates STXS with a GF Score™ of 66/100 and a GF Value™ of $2.31 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Stereotaxis ranks worse than 79.11% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.06 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Stereotaxis's Beneish M-Score or its related term are showing as below:
STXS'
s Beneish M-Score Range Over the Past 10 Years
Min: -5.07 Med: -2.73 Max: 28.69
Current: -2.06
During the past 13 years, the highest Beneish M-Score of Stereotaxis was 28.69. The lowest was -5.07. And the median was -2.73.
Stereotaxis Beneish M-Score Related Terms
Stereotaxis Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Stereotaxis's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STXS vs EMBC, KRMD, PDEX: Beneish M-Score Comparison
For the Medical Instruments & Supplies subindustry, Stereotaxis's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stereotaxis Beneish M-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stereotaxis's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Stereotaxis's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Stereotaxis for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.9618
+
0.528 * 0.9916
+
0.404 * 0.7907
+
0.892 * 1.134
+
0.115 * 0.7065
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.8612
+
4.679 * -0.117157
-
0.327 * 0.7942
=
-2.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(1.199 / (1.199 + 8.786))
/
(1.58 / (1.58 + 7.716))
=
0.12008
/
0.169966
=
0.7065
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-21.681 - -0.003
-
-15.348)
/
54.03
=
-0.117157
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Stereotaxis has a M-score of -2.06 suggests that the company is unlikely to be a manipulator.
Stereotaxis (STXS) has a Beneish M-Score of -2.06 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Stereotaxis and its competitors. According to the industry distribution chart, Stereotaxis ranks #606 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 79.1%.
Is Stereotaxis' Beneish M-Score too high?
Stereotaxis' current Beneish M-Score is -2.06. Based on the distribution chart, Stereotaxis ranks #606 out of 766 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Stereotaxis has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stereotaxis' Beneish M-Score compare to EMBC and KRMD?
According to the Medical Devices & Instruments industry distribution chart, Stereotaxis ranks #606 out of 766 companies for Beneish M-Score. This places Stereotaxis in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Stereotaxis and its competitors. Stereotaxis's current Beneish M-Score is -2.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stereotaxis stock overvalued right now?
Based on GuruFocus' analysis, Stereotaxis (STXS) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.31, compared to a current price of $1.64 — trading 29.2% below its estimated fair value. The current Beneish M-Score is -2.06. Stereotaxis' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Stereotaxis (STXS), the current Beneish M-Score is -2.06 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stereotaxis (STXS) Overvalued in 2026?
Based on GuruFocus' analysis, Stereotaxis stock appears to be undervalued.
The current stock price of $1.64 is trading 29.2% below its estimated GF Value™ of $2.31.
GuruFocus considers Stereotaxis to be Modestly Undervalued.
Key valuation signals for STXS:
Beneish M-Score: -2.06
GF Value™: $2.31 vs. price of $1.64 (29.2% below fair value)
No single metric tells the full story. See the STXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
66GF Score
Get the complete analysis for STXS
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STXS has been successfully added to your 
